Search results for "observational [Methods]"

showing 10 items of 897 documents

Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis

2021

Importance Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging. Objective To evaluate changes in the prognosis of POMS over time in association with changes in therapeutic and managing standards. Design, Setting, and Participants Retrospective, multicenter, observational study. Data were extracted and collected in May 2019 from the Italian MS Registry, a digital database including more than 59 000 patients. Inclusion criteria were…

MaleRegistriePediatricsAdolescent; Adult; Age of Onset; Aged; Child; Child Preschool; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Registries; Retrospective Studies; Risk Factors; Young Adult; Disabled Persons; Disease ProgressionRisk of Disability0302 clinical medicineRisk FactorsRetrospective StudieMultiple Sclerosi030212 general & internal medicineRegistriesAge of OnsetChildOriginal InvestigationHazard ratioConfoundingMiddle Agedpediatric-onset MS (POMS)Italytherapeutic and managing standardsChild PreschoolDisease ProgressionSettore MED/26 - NeurologiaFemaleDisabled PersonHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentMEDLINEProfile of mood states03 medical and health sciencesYoung AdultmedicineHumansIn patientDisabled PersonsPreschoolpediatric-onset MS (POMS) therapeutic and managing standardsRetrospective StudiesAgedExpanded Disability Status Scalebusiness.industryPediatric-Onset Multiple SclerosisMultiple sclerosisRisk Factormedicine.diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Spontaneous Breathing in Early Acute Respiratory Distress Syndrome

2019

Supplemental Digital Content is available in the text.

MaleRespiratory ratemedicine.medical_treatmentlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Clinical InvestigationsRespiration Artificial/methodsmechanical ventilationCritical Care and Intensive Care MedicineNOPositive-Pressure Respiration03 medical and health sciences0302 clinical medicineacute respiratory distress syndrome controlled mechanical ventilation spontaneous breathing supported ventilationRespiratory RatemedicineHumansProspective StudiesProspective cohort studyArtificial/methodsMechanical ventilationRespiratory Distress Syndromebusiness.industryRespirationConfounding030208 emergency & critical care medicineOdds ratioTidal Wavesacute respiratory distress syndromeMiddle AgedRespiration Artificial3. Good healthcontrolled mechanical ventilationTreatment Outcome030228 respiratory systemAnesthesiasupported ventilationBreathingComputingMethodologies_DOCUMENTANDTEXTPROCESSINGspontaneous breathingRespiratory Distress Syndrome Adult/physiopathologyObservational studyARDSFemaleAdult/physiopathologybusinessRespiratory InsufficiencyCohort studyCritical Care Medicine
researchProduct

Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies

2020

Multiple studies have suggested that ω-3 fatty acid intake may have a protective effect on cancer risk; however, its true association with cancer risk remains controversial. We performed an umbrella review of meta-analyses to summarize and evaluate the evidence for the association between ω-3 fatty acid intake and cancer outcomes. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews from inception to December 1, 2018. We included meta-analyses of observational studies that examined associations between intake of fish or ω-3 fatty acid and cancer risk (gastrointestinal, liver, breast, gynecologic, prostate, brain, lung, and skin) and determined the level of evidence of…

MaleRiskOncologymedicine.medical_specialty[SDV]Life Sciences [q-bio]BFMedicine (miscellaneous)ReviewCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerω-3 fatty acidMeta-Analysis as TopicNeoplasmsInternal medicineFatty Acids Omega-3medicineAnimalsHumanscancer030212 general & internal medicineω-3 fatty acid fish cancer umbrella review meta-analysischemistry.chemical_classificationfishNutrition and Dieteticsumbrella reviewbusiness.industryEndometrial cancerFishesFatty acidCancermedicine.diseaseR13. Good healthmeta-analysisObservational Studies as TopicchemistryCase-Control Studies030220 oncology & carcinogenesisMeta-analysisFemaleSkin cancerbusinessLiver cancerFood Science
researchProduct

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

2014

Reducing low-density lipoprotein cholesterol (LDL-C) levels using statins is associated with significant reductions in cardiovascular (CV) events in a wide range of patient populations. Although statins are generally considered to be safe, recent studies suggest they are associated with an increased risk of developing Type 2 diabetes (T2D). This led the US Food and Drug Administration (FDA) to change their labelling requirements for statins to include a warning about the possibility of increased blood sugar and HbA1c levels and the European Medicines Agency (EMA) to issue guidance on a small increased risk of T2D with the statin class. This review examines the evidence leading to these clai…

MaleSettore MED/09 - Medicina Internaendocrine system diseasesHSM MEDHydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effectsAnticholesteremic Agents/adverse effectsMedizin1567-5688ComorbidityType 2 diabetesPharmacologyDiabeteHydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosageCardiovascularFasting/bloodCohort StudiesRisk FactorsAnticholesteremic Agents/administration & dosageDiabetes Mellitus Type 2/prevention & controlMulticenter Studies as TopicMedicineT2DDiabetisAnticholesteremic AgentsDiabetesHemoglobin A Glycosylated/analysisFastingGeneral MedicineMiddle AgedDiabetogenicityCVDClinical PracticeObservational Studies as TopicCholesterol LDL/bloodCardiovascular DiseasesPractice Guidelines as Topiclipids (amino acids peptides and proteins)Disease SusceptibilityCardiology and Cardiovascular MedicineRisk assessmentCardiovascular Diseases/prevention & controlCohort studyAdultmedicine.medical_specialtyStatinHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic usemedicine.drug_classAnticholesteremic Agents/therapeutic useHydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacologyDiabetes Mellitus Type 2/etiologyRisk AssessmentMulticenter Studies as Topic/statistics & numerical dataPrediabetic StateMeta-Analysis as TopicDiabetes mellitusInternal MedicineHumansIntensive care medicinePrediabetic State/epidemiologyGlycated HemoglobinStatins; Diabetes; Diabetogenicity; T2D; Cardiovascular; CVDbusiness.industryCardiovascular Diseases/epidemiologyStatinsStatinnutritional and metabolic diseasesCholesterol LDLmedicine.diseaseComorbidityAnticholesteremic Agents/pharmacologyDiabetes Mellitus Type 2/epidemiologyDiabetes Mellitus Type 2Estatines (Medicaments cardiovasculars)Observational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessObservational Study as TopicForecasting
researchProduct

A case control study of statin and magnesium administration in patients after aneurysmal subarachnoid hemorrhage: incidence of delayed cerebral ische…

2008

To analyse the effect of the implementation of statin and magnesium treatment on delayed cerebral ischemia (DCI) and 14 day mortality in patients with subarachnoid hemorrhage (SAH).Retrospective, single-center, observational case control study. One hundred SAH patients received either simvastatin and magnesium, solely statin or no treatment.Eighteen percent (n=5) of patients receiving statin and magnesium treatment developed a DCI whereas 24% (n=5) in the statin group and 16% (n=8) in the control group had DCI. Dead by day 14 was registered in 18% (n=5) of patients in the statin and magnesium group, in 10% (n=2) in the statin group and in 27% (n=14) in the control group. None of the results…

MaleSimvastatinStatinSubarachnoid hemorrhagemedicine.drug_classIschemia610 Medicine & healthBrain Ischemia10180 Clinic for NeurosurgeryStatistical significancemedicineHumansMagnesiumcardiovascular diseasesRetrospective Studiesbusiness.industryIncidence (epidemiology)Anticholesteremic AgentsCase-control studynutritional and metabolic diseasesGeneral MedicineMiddle AgedSubarachnoid Hemorrhagemedicine.diseaseSurvival RateTreatment Outcome2728 Neurology (clinical)NeurologySimvastatinAnesthesiaCase-Control Studies2808 Neurologylipids (amino acids peptides and proteins)Observational studyFemaleNeurology (clinical)businessmedicine.drug
researchProduct

Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis.

2011

Background Therapy of atopic dermatitis (AD) relies on immunosuppression and/or UV irradiation. Here, we assessed clinical efficacy and histopathological alterations induced by blue light-treatment of AD within an observational, non-interventional study. Methodology/Principal Findings 36 patients with severe, chronic AD resisting long term disease control with local corticosteroids were included. Treatment consisted of one cycle of 5 consecutive blue light-irradiations (28.9 J/cm2). Patients were instructed to ask for treatment upon disease exacerbation despite interval therapy with topical corticosteroids. The majority of patients noted first improvements after 2–3 cycles. The EASI score w…

MaleSkin PhysiologyAnatomy and PhysiologyLightmedicine.medical_treatmentlcsh:MedicinePediatric DermatologyAntigen Processing and RecognitionAtopic DermatitisDiseasePediatricsQuality of lifeYoung adultlcsh:ScienceSkinMultidisciplinarymedicine.diagnostic_testT CellsAllergy and HypersensitivityPhysicsElectromagnetic RadiationPhotodermatology and Skin AgingImmunosuppressionAtopic dermatitisMiddle Agedmedicine.anatomical_structureTreatment OutcomePatient SatisfactionObservational StudiesMedicineFemaleWhole-Body IrradiationResearch ArticleAdultmedicine.medical_specialtyLangerhans cellClinical Research DesignImmune CellsImmunologyColorDermatologyDermatitis AtopicYoung AdultUltraviolet RadiationBiopsymedicineHumansSerologic TestsBiologybusiness.industrylcsh:Rmedicine.diseaseDermatologyClinical trialImmune SystemChronic DiseaseQuality of Lifelcsh:QClinical ImmunologybusinessPloS one
researchProduct

The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study

2017

This study evaluated the effect of ≥6 months of transdermal rotigotine on non-motor and motor symptoms of patients with advanced Parkinson's disease.The study was conducted in Spain between September 2011 and December 2012 (ClinicalTrials.gov: NCT01504529). The primary efficacy variable was the change from baseline in non-motor symptoms, as assessed by changes in Parkinson's Disease Non-Motor Symptoms Questionnaire total scores at 6 months. Secondary endpoints included the assessment of motor symptoms by Unified Parkinson's Disease Rating Scale III scores.Data from 378 patients (mean age: 70.2 years; 56.9% male) with Parkinson's disease receiving rotigotine from were collected. Mean disease…

MaleSleep Wake Disordersmedicine.medical_specialtyParkinson's diseaseTetrahydronaphthalenesThiophenesDiseaseAdministration CutaneousMotor symptoms03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesProduct Surveillance PostmarketingmedicineHumans030212 general & internal medicineAgedRetrospective StudiesTransdermalAged 80 and overbusiness.industryGeneral NeuroscienceParkinson DiseaseRotigotineGeneral MedicineUrination Disordersmedicine.diseaseClinical PracticeTreatment OutcomeSpainDopamine AgonistsPhysical therapyNon motorFemaleObservational studyCognition Disordersbusiness030217 neurology & neurosurgerymedicine.drugInternational Journal of Neuroscience
researchProduct

Social cognition and executive functions in children and adolescents with focal epilepsy

2020

Objectives: Deficits in facial emotion recognition and Theory of Mind are frequent in patients with epilepsy. Although this evidence, studies on pediatric age are few and the relation between these abilities and other cognitive domain remains to be better elucidated. The purpose of our study is to evaluate facial emotion recognition and Theory of Mind in children and adolescents with focal epilepsy, and correlate them with intelligence and executive functions. Materials and methods: Our work is a cross-sectional observational study. Sixty-two children and adolescents aged between 7-16 years diagnosed by focal epilepsy and 32 sex/age-matched controls were recruited. All participants were adm…

MaleSocial CognitionAdolescentEmotionsTheory of MindNeuropsychological TestsEpilepsiesAdolescentsExecutive Function03 medical and health sciencesEpilepsy0302 clinical medicineRaven's Progressive MatricesSocial cognition030225 pediatricsTheory of mindmedicineHumansIn patientChildChildrenEpilepsyCognitionGeneral MedicineExecutive functionsmedicine.diseaseSettore MED/39 - Neuropsichiatria InfantileCross-Sectional StudiesPediatrics Perinatology and Child HealthAdolescents Children Epilepsy Executive function Social cognition Theory of mindFemaleObservational studyEpilepsies PartialNeurology (clinical)Psychology030217 neurology & neurosurgeryPartialClinical psychologyEuropean Journal of Paediatric Neurology
researchProduct

Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute resp…

2022

Contains fulltext : 252214.pdf (Publisher’s version ) (Open Access) BACKGROUND: Geoeconomic variations in epidemiology, the practice of ventilation, and outcome in invasively ventilated intensive care unit (ICU) patients without acute respiratory distress syndrome (ARDS) remain unexplored. In this analysis we aim to address these gaps using individual patient data of four large observational studies. METHODS: In this pooled analysis we harmonised individual patient data from the ERICC, LUNG SAFE, PRoVENT, and PRoVENT-iMiC prospective observational studies, which were conducted from June, 2011, to December, 2018, in 534 ICUs in 54 countries. We used the 2016 World Bank classification to defi…

MaleSociodemographic FactorsRespiration Artificial/methodsARDS ; mechanical ventilationSeverity of Illness IndexNOSettore MED/41 - ANESTESIOLOGIA80 and overTidal VolumeHumansHospital MortalityProspective Studiesddc:610Developing CountriesAgedHospital Mortality/trendsAged 80 and overDeveloped Countries/statistics & numerical dataDeveloping Countries/statistics & numerical dataRespirationDeveloped CountriesArticlesGeneral Medicineacute respiratory distress syndromeLength of StayMiddle AgedRespiration ArtificialIntensive Care UnitsObservational Studies as Topiclnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Length of Stay/statistics & numerical dataArtificialIntensive Care Units/statistics & numerical dataIncomeFemaleARDS
researchProduct

Fluid challenges in intensive care: the FENICE study: a global inception cohort study

2015

Background: Fluid challenges (FCs) are one of the most commonly used therapies in critically ill patients and represent the cornerstone of hemodynamic management in intensive care units. There are clear benefits and harms from fluid therapy. Limited data on the indication, type, amount and rate of an FC in critically ill patients exist in the literature. The primary aim was to evaluate how physicians conduct FCs in terms of type, volume, and rate of given fluid; the secondary aim was to evaluate variables used to trigger an FC and to compare the proportion of patients receiving further fluid administration based on the response to the FC. Methods: This was an observational study conducted i…

MaleSoins intensifs réanimationmedicine.medical_treatmentCohort Studies; Female; Humans; Male; Middle Aged; Practice Patterns Physicians'; Critical Care; Fluid Therapy; Critical Care and Intensive Care MedicinePractice PatternsESICM Trial GroupCritical Care and Intensive Care MedicineRESPONSIVENESSCohort StudiesSeven-Day Profile PublicationMedicine and Health SciencesPractice Patterns Physicians'FENICE InvestigatorsCIRCULATORY SHOCKintensive careddc:617RENAL REPLACEMENT THERAPYMiddle Aged3. Good healthOF-THE-LITERATURESHOCKFemalelipids (amino acids peptides and proteins)Erratumintensive care fluid therapyfluidsLife Sciences & BiomedicineCRITICALLY-ILL PATIENTSHumanCohort studymedicine.medical_specialtyCritical CareHYDROXYETHYL STARCH 130/0.4MEDLINE1117 Public Health and Health ServicesNOfluid therapyCritical Care MedicineCIRCULATORYGeneral & Internal MedicineIntensive careAnesthesiologyPATIENTSmedicinecohort studyHumansRenal replacement therapyIntensive care medicineintensive care; fluids; cohort studyPhysicians'Science & TechnologyCRITICALLY-ILLbusiness.industrySeptic shockSEPTIC SHOCK1103 Clinical Sciences3126 Surgery anesthesiology intensive care radiologymedicine.diseaseEmergency & Critical Care MedicineARTERIAL-PRESSURESEVERE SEPSISClinical trialFluid TherapyObservational studyCohort Studiebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyTASK-FORCE
researchProduct